Clinical trials: Stomach Tumor
Submucosal Tumor of Stomach
Endoscopic Full Thickness Resection Without Exposure to Peritoneum
This study evaluates the feasibility of endo-laparoscopic full-thickness resection with simple suturing technique which did not expose gastric mucosa to peritoneum (simple non-exposure EFTR) in patients with gastric tumor.
- Trial name
- NCT02764944
- Testing
- simple non-exposure EFTR
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- National Cancer Center, Korea
Gastric Cancer Stage IV, Peritoneal Metastasis
Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)
The goal of this clinical trial is to evaluate the impact of conversion surgery on overall survival (OS) in patients with gastric cancer peritoneal metastases (GCPM) who show a good response to preoperative systemic therapy…
- Trial name
- CONVERGENCE (NCT07241715)
- Testing
- Conversion Surgery, Systemic Therapy/Standard of Care
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- National University Hospital, Singapore
Neuroendocrine Tumors
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
This is a non-randomized, phase II, open label study. The purpose of this study is to estimate Progression Free Survival (PFS) after treatment with Peptide Receptor Radionuclide Therapy (PRRT) 177Lu-DOTATOC standard dose (up to…
- Trial name
- NCT04194125
- Testing
- 177Lu-DOTATOC
- Where
- Poland
- Volunteers
- 25 people
- Sponsor
- University of Warmia and Mazury
Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Alpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases.
- Trial name
- NCT07515625
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Volunteers
- 46 people
- Sponsor
- Fudan University
Pancreatic Adenocarcinoma, Gastric Adenocarcinoma
Resilience and Exercise in Advanced Cancer Treatment
This is a pilot study to evaluate the feasibility of, adherence to, and early efficacy of Band Together, a strength-training and walking program (intervention arm) vs.
- Conditions
- Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
- Trial name
- REACT (NCT02680990)
- Testing
- Band Together, Exercise Education
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Milton S. Hershey Medical Center
Gastric Cancer
Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Study H3E-MW- S108 is a multicenter, single arm, open-label Phase 2 study to determine the response rate of pemetrexed plus cisplatin in patients with Stage IV gastric cancer, not amenable to curative surgery, or recurrence after…
- Trial name
- NCT00415168
- Testing
- pemetrexed, cisplatin
- Where
- 6 sites in Russia
- Volunteers
- 53 people
- Sponsor
- Eli Lilly and Company
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience
Abdominal Surgery
Preoperative Nutritional Assessment for Predicting Complications Risk in Patients Undergoing Abdominal Surgery
Predictive Value of Various Nutritional Screening and Assesment Tools and a Surgery Scoring System (POSSUM Score) for Predicting Postoperative Complications in Patients Scheduled for Abdominal Surgery.
- Trial name
- NCT03719508
- Where
- Greece
- Volunteers
- 450 people
- Sponsor
- Evangelismos Hospital
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01498289
- Testing
- FOLFOX regimen, docetaxel, fluorouracil
- Where
- 508 sites in United States
- Volunteers
- 213 people
- Sponsor
- SWOG Cancer Research Network
Gastric GIST
Study On Safety Of Endoscopic Resection For 2-5cm Gastric Gastrointestinal Stromal Tumor
This research is a prospective, multi-center trial for endoscopic resection and laparoscopic partial gastrectomy in patients with 2-5cm gastric gastrointestinal stromal tumor.
- Trial name
- NCT04751591
- Testing
- Endoscopic resection, Laparoscopic partial gastrectomy
- Volunteers
- 260 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastroenteropancreatic Neuroendocrine Tumor
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
- Trial name
- NCT03017690
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ipsen
Gastric Cancer
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer
The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced…
- Trial name
- NCT00952497
- Testing
- Cisplatin, Capecitabine, Telatinib
- Where
- 11 sites in United States, Spain
- Volunteers
- 48 people
- Sponsor
- ACT Biotech, Inc
Advanced Gastric Cancer
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
Fruquintinib once daily in 4 weeks treatment cycle (three weeks on and one week off) in combination with Paclitaxel 80mg/㎡（day1, 8, 15 of 4 weeks cycle) was well tolerated and demonstrated encouraging preliminary clinical…
- Trial name
- FRUTIGA (NCT03223376)
- Testing
- fruquintinib +paclitaxel
- Where
- 7 sites in China
- Volunteers
- 703 people
- Sponsor
- Hutchison Medipharma Limited
Gastric Cancer Patients Treated by Subtotal Gastrectomy
Obestatin Change in Distal Gastrectomy
According to Seoul cancer registry data (2000), cancer became the leading cause of death in Korea, accounting for 23.9% of all deaths and gastric cancer is the most prevalent malignant neoplasm, comprising 20.8% of all cancers.
- Trial name
- NCT00822718
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Breast Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety of Nanoxel M Inj.
Study to evaluate the safety of Nanoxel M inj. administration in patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT04066335
- Where
- South Korea
- Volunteers
- 1,498 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy.
- Trial name
- NCT04435652
- Testing
- QL1604, Nab-paclitaxel, Paclitaxel
- Where
- China
- Volunteers
- 492 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer
Second-line chemotherapy represents an option in gastric cancer, especially for patients with adequate performance status. Two randomized phase III trials comparing 2nd-line docetaxel with best-supportive care have reported a…
- Trial name
- MICADO (NCT02007148)
- Testing
- capecitabine, Docetaxel
- Where
- 2 sites in Italy
- Volunteers
- 51 people
- Sponsor
- International Group of Endovascular Oncology
Gastric Cancer
A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer
This is a prospective pilot study to evaluate the safety and feasibility of neoadjuvant transcatheter infusion and embolism (TACiE) in patients with locally advanced adenocarcinoma of stomach and gastroesophageal junction.
- Trial name
- NCT05396326
- Testing
- Oxaliplatin, Teysuno, Transarterial arterial chemoinfusion and embolism (TACiE)
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital